Home › Trial NCT07836101
Study of Sarilumab With Immune Checkpoint Inhibitor Rechallenge in Patients With Clinically Significant Immune Related Adverse Events
- Trial IDNCT07836101
- StatusNot Yet Recruiting
- PhasePhase 2
- Study typeInterventional
- SponsorSidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Enrollment41
- Start date2026-12
- ConditionsAny Advanced Solid Tumors
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.